Abselion

Abselion is a private, pre-revenue platform company offering an innovative electrochemical detection system for biologics quantification. Its core technology, the Amperia™ instrument powered by RED (Redox Electrochemical Detection), is designed to simplify and accelerate protein measurement, enabling faster decision-making in biopharmaceutical R&D and process development. The company, a University of Cambridge spin-out, is expanding commercially with a recent US subsidiary establishment and key leadership appointments, targeting the growing market for analytical tools in biologics and gene therapy development. Its business model revolves around selling instruments, assay kits, sensors, and consumables to research and bioprocessing labs.

Amperia™ instrument powered by RED (Redox Electrochemical Detection) technology for direct, real-time quantification of biologics (antibodies, AAV capsids, His-tagged proteins) from crude samples.

Abselion competes in the protein quantification market against traditional methods (ELISA, spectrophotometry) and instruments from large players like Thermo Fisher, Agilent, and Bio-Rad. Its differentiation lies in speed, simplicity, and crude sample analysis, positioning it as a potential disruptor for specific use-cases in early-stage research and process development.